GAIN THERAPEUTICS, INC (GANX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -19.29M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 10.10M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-19.29M | (m) | (m) | $10.10M | (m) | (m) |
| 2026-03-31 | $-19.69M | (m) | (m) | $10.72M | (m) | (m) |
| 2025-12-31 | $-18.71M | (m) | (m) | $10.21M | (m) | (m) |
| 2025-09-30 | $-17.58M | (m) | (m) | $9.09M | (m) | (m) |
| 2025-06-30 | $-17.25M | (m) | (m) | $8.86M | (m) | (m) |
| 2025-03-31 | $-20.34M | (m) | (m) | $10.54M | (m) | (m) |
| 2024-12-31 | $-20.35M | (m) | (m) | $10.79M | (m) | (m) |
| 2024-09-30 | $-21.43M | (m) | (m) | $11.94M | (m) | (m) |
| 2024-06-30 | $-21.85M | (m) | (m) | $11.69M | (m) | (m) |
| 2024-03-31 | $-21.40M | (m) | (m) | $11.24M | (m) | (m) |
| 2023-12-31 | $-22.25M | $55.18K | (m) | $11.52M | (m) | -40328.26% |
| 2023-09-30 | $-22.41M | $55.18K | (m) | $11.42M | (m) | -40607.29% |
| 2023-06-30 | $-22.27M | $55.18K | (m) | $11.02M | (m) | -40364.41% |
| 2023-03-31 | $-19.72M | $150.28K | (m) | $9.61M | (m) | -13120.90% |
| 2022-12-31 | $-17.78M | $132.64K | (m) | $8.38M | (m) | -13402.48% |
| 2022-09-30 | $-16.42M | $168.98K | (m) | $7.58M | (m) | -9719.80% |
| 2022-06-30 | $-16.31M | $184.95K | (m) | $8.09M | (m) | -8818.31% |
| 2022-03-31 | $-14.65M | $166.20K | (m) | $7.30M | (m) | -8813.48% |
| 2021-12-31 | $-13.83M | $133.93K | (m) | $7.16M | (m) | -10323.59% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-3.48M | $28.88K | (m) | $2.26M | (m) | -12047.54% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |